このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HA380 Hemoadsorption Combined With Continuous Renal Replacement Therapy Versus Continuous Renal Replacement Therapy Alone in Septic Shock (HA380-SHOCK)

2026年11月14日 更新者:Bui Viet Hoan、The 108 Military Central Hospital

Efficacy of Continuous Renal Replacement Therapy Combined With the HA380 Hemoadsorption Cartridge Versus Continuous Renal Replacement Therapy Alone in the Treatment of Septic Shock: A Single-Center, Open-Label, Assessor-Blinded, Randomized Controlled Trial

The goal of this clinical trial is to learn whether adding an HA380 hemoadsorption cartridge to continuous renal replacement therapy (CRRT) helps adults with septic shock and acute kidney injury requiring CRRT recover from shock better than CRRT alone. Septic shock is a life-threatening condition in which an infection triggers an excessive inflammatory response, causing very low blood pressure and organ failure. The HA380 cartridge is a device placed in the CRRT blood circuit that is designed to remove inflammatory molecules (cytokines) from the blood.

The main question it aims to answer is: Does CRRT combined with the HA380 cartridge result in a lower blood lactate level (a marker of poor oxygen delivery to the body's tissues) at 24 hours than CRRT alone? Researchers will also compare the two groups in terms of the amount of blood-pressure-supporting medicines needed, blood levels of inflammatory cytokines, organ function, time to recovery from shock, need for organ support, length of intensive care unit (ICU) and hospital stay, survival up to 28 days, and side effects.

Participants will:

  • Be randomly assigned to receive either CRRT combined with the HA380 cartridge or CRRT alone, in addition to the same standard septic shock care
  • If assigned to the HA380 group, receive three HA380 cartridges consecutively, each for 6 hours (18 hours in total), followed by CRRT alone as needed
  • Have their vital signs, medicine doses and blood tests recorded before treatment and at set times up to day 7
  • Be followed up for survival and recovery until day 28

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Background: Septic shock remains a leading cause of death in ICUs. Excessive release of inflammatory cytokines ("cytokine storm") contributes to vasoplegia, tissue hypoperfusion and multiple organ dysfunction. The HA380 cartridge (Jafron Biomedical, China) is a neutral macroporous resin hemoadsorption device that removes middle-molecular-weight substances, including cytokines, and can be used in series with a CRRT circuit. It is licensed for clinical use in Vietnam by the Ministry of Health (Decision No. 266/QD-BYT, 22 January 2025). Available data on HA380 combined with CRRT in septic shock come mainly from retrospective single-center studies, and randomized evidence is lacking. The Surviving Sepsis Campaign 2026 guidelines issue a weak recommendation against the routine use of blood purification therapies, including hemoperfusion, in sepsis and septic shock, reflecting the limited and uncertain evidence. This trial addresses that evidence gap in a selected population with marked hyperinflammation (IL-6 >500 pg/mL), septic shock requiring high-dose vasopressors and acute kidney injury already requiring CRRT, in whom HA380 can be added to an existing extracorporeal circuit. HA380 is used only within this randomized trial, under Ethics Committee approval and written informed consent.

Objectives: (1) to compare the effects of CRRT combined with HA380 hemoadsorption versus CRRT alone on tissue perfusion, hemodynamics, inflammation and organ function in septic shock; (2) to describe clinical outcomes and safety of the two strategies.

Design: Prospective, single-center, open-label, assessor-blinded, randomized controlled trial with two parallel groups (1:1), conducted in the Medical and Toxicological Intensive Care Unit, 108 Military Central Hospital, Hanoi, Vietnam. Planned recruitment: November 2026 to October 2028, with follow-up to November 2028. The study is part of a doctoral (PhD) program of the 108 Institute of Clinical Medical and Pharmaceutical Sciences.

Participants: Adults with septic shock (Sepsis-3) requiring norepinephrine ≥0.4 µg/kg/min (or equivalent), with plasma interleukin-6 (IL-6) >500 pg/mL (Elecsys IL-6, Cobas system) and acute kidney injury with at least one indication for CRRT.

Randomization, allocation concealment and blinding: After written informed consent (from the patient or legally authorized representative), participants are randomized 1:1 by permuted-block randomization with randomly varying block sizes. The sequence is generated in R (blockrand package) by an independent person not involved in recruitment or treatment, and concealed in sequentially numbered, opaque, sealed envelopes (SNOSE). Treating clinicians cannot be blinded. The person scoring SOFA and SOFA-2, the laboratory staff performing cytokine assays and the statistician are blinded to allocation. To limit bias from the open-label design, vasoactive drugs are titrated in both groups by the same written protocol based on invasive arterial pressure (MAP target ≥65 mmHg, or ≥60 mmHg in patients aged ≥65 years; vasopressors are weaned in the following order: epinephrine, norepinephrine, and then vasopressin).

Interventions: Apart from the study intervention, both groups receive the same standard septic shock management according to the Surviving Sepsis Campaign 2026 guidelines and baseline CRRT started as soon as possible after randomization (within 2 hours): continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (each M100 used for a maximum of 24 hours), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, and unfractionated heparin anticoagulation per study protocol (no anticoagulation if platelet count <50 ×10⁹/L). In the intervention group, the HA380 cartridge is connected in series after the M100 hemofilter, before blood returns to the patient; three HA380 cartridges are used consecutively for 6 hours each (18 hours of hemoadsorption), after which CRRT alone continues as clinically indicated. If a cartridge clots early, it is removed without replacement, CRRT continues, and the next cartridge is connected at the next scheduled time. Full adherence is defined as use of all three cartridges per protocol with a total hemoadsorption time of at least 16 hours. To limit antibiotic underdosing, loading doses are given before HA380 connection when possible, vancomycin and aminoglycoside levels are monitored in both groups when available, and all antibiotics given in the first 24 hours are recorded.

Time points: R = randomization (time-to-event outcomes are counted from R). T0 = immediately before the first CRRT session (≤2 hours after R). Hemodynamics, vasoactive doses (summarized as VIS and norepinephrine equivalent dose, NEE) and arterial blood gases including lactate (RAPIDPoint 500 analyzer in the ICU, same device for all measurements) are recorded at T0 and at 6, 12, 18, 24, 48 and 72 hours after CRRT initiation. Plasma IL-1β, IL-6, IL-8, IL-10 and TNF-α are measured at T0 and 24 hours (Luminex 200, ProcartaPlex multiplex immunoassay, Vietnam Military Medical University). Hematology, liver and renal function, coagulation, CRP, procalcitonin, ferritin, LDH, SOFA and SOFA-2 scores and the number of organ failures (Knaus criteria) are assessed at T0, day 3 and day 7. APACHE II, SAPS II and mNUTRIC are recorded at baseline. Clinical outcomes are followed to day 28 (D28).

Sample size: Based on An et al. (2025), the mean reduction in lactate after 24 hours of treatment was 1.61 versus 1.04 mmol/L (difference 0.57 mmol/L; pooled SD of 24-hour lactate 0.81 mmol/L; standardized effect size d ≈ 0.70). With two-sided α = 0.05 and 80% power, 32 participants per group are required; inflated by approximately 9% for attrition, 35 per group (70 in total) will be enrolled.

Statistical analysis: The statistical analysis plan is finalized before database lock and before unblinding of the statistician. The primary analysis is intention-to-treat (all randomized participants analyzed as allocated). The primary outcome (arterial lactate at 24 hours) is analyzed by ANCOVA with treatment group and baseline lactate, reporting the adjusted mean difference with 95% CI; participants who die before 24 hours are assigned the highest lactate value observed in the whole sample. Pre-specified sensitivity analyses: (1) log-transformed lactate; (2) additional adjustment for baseline log IL-6, SOFA and epinephrine dose; (3) survivors to 24 hours only; (4) hierarchical rank test (death before 24 hours ranked worst, survivors ranked by lactate); (5) per-protocol population. Repeated secondary measures are analyzed with linear mixed models adjusted for baseline; time to shock resolution with a Fine-Gray competing-risk model (death as competing event); mortality and dialysis dependence with risk ratios, risk differences, Kaplan-Meier, log-rank and Cox models; free-day outcomes with Mann-Whitney U and Hodges-Lehmann estimates; Holm correction across the five cytokines. Pre-specified subgroup: baseline IL-6 below/above the sample median (interaction test). Baseline IL-6 used for the subgroup analysis and sensitivity analysis (2) is the value measured by Elecsys IL-6 at screening (the same assay used for eligibility). No randomized participant is excluded from the primary (intention-to-treat) analysis.

Safety: Adverse events are defined using pre-specified study criteria and graded with CTCAE version 6.0; for abnormalities already present at baseline (e.g., thrombocytopenia, electrolyte disturbances), only treatment-emergent events are counted: a new event of grade ≥1 after T0 in a participant with grade 0 at T0, or worsening by at least one grade from T0. Monitoring windows: hypotension within 30 minutes after CRRT connection and after each HA380 cartridge change (6, 12 and 18 hours); bleeding, thrombocytopenia and hemolysis up to day 7; electrolyte disturbances until the end of CRRT or day 7, whichever comes first; hypothermia by hourly core temperature during CRRT (lowest value recorded every 6 hours in the first 24 hours, then daily) until the end of CRRT or day 7, whichever comes first; anaphylaxis within 72 hours; catheter occlusion, catheter-site infection and catheter-related venous thrombosis daily up to day 14. Extracorporeal circuit incidents (hemofilter membrane rupture, hemofilter clotting, early HA380 clotting, technical machine stoppage) are classified as device deficiencies, defined by objective machine-alarm and observation criteria, and recorded in real time with the machine alarm log until the end of CRRT or 72 hours after CRRT initiation, whichever comes first. Serious adverse events are reported to the Ethics Committee according to national regulations.

Ethics, funding and conflicts of interest: The protocol was approved by the Ethics Committee in Biomedical Research, 108 Military Central Hospital (Certificate No. 7197/GCN-BV, 11 September 2026). HA380 cartridges and cytokine assays are funded by Thanh Phuong Co., Ltd., the Vietnamese distributor of HA380 (donation letter No. 0805/CV-TPC, 8 May 2026). The company has no role in study design, data collection, data analysis, interpretation of results, manuscript preparation or the decision to publish. Participants incur no additional costs.

研究の種類

介入

入学 (推定)

70

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Hanoi、ベトナム
        • The 108 Military Central Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥18 years
  • Septic shock according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, 2016)
  • Norepinephrine ≥0.4 µg/kg/min, or an equivalent vasopressor dose, required to maintain the target mean arterial pressure
  • Plasma interleukin-6 (IL-6) concentration >500 pg/mL (Elecsys IL-6, Cobas system)
  • Acute kidney injury with at least one indication for continuous renal replacement therapy: serum potassium ≥6.5 mmol/L; pH <7.2 not due to pure respiratory acidosis; oliguria <0.3 mL/kg/h for ≥24 hours or anuria for ≥12 hours; fluid overload unresponsive to diuretics, or pulmonary edema; or uremic syndrome
  • Randomization within 24 hours of septic shock onset
  • Written informed consent obtained from the patient or the legally authorized representative

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Malignancy currently treated with chemotherapy or radiotherapy, neutrophil count <1 ×10⁹/L, immunosuppressive therapy after organ transplantation, or AIDS
  • Chronic kidney disease on maintenance dialysis, Child-Pugh C cirrhosis, or NYHA class IV heart failure
  • Active bleeding, or platelet count <20 ×10⁹/L refractory to platelet transfusion
  • Allergy to heparin or history of heparin-induced thrombocytopenia
  • Concomitant hemorrhagic shock or anaphylactic shock
  • Expected death within 24 hours, or a do-not-resuscitate order or a family decision to withdraw life-sustaining treatment
  • Cardiac arrest during the current illness before randomization
  • Continuous renal replacement therapy or any hemoadsorption already received during the current hospital admission before randomization
  • Patient or legally authorized representative declines participation

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:CRRT + HA380 Hemoadsorption

Baseline CRRT (CVVHDF, Prismaflex, M100 hemofilter) plus three consecutive HA380 cartridges, 6 hours each (18 hours in total), connected in series after the M100 hemofilter; CRRT alone continues afterwards as clinically indicated. Standard septic shock care per the Surviving Sepsis Campaign 2026 guidelines.

Single-use neutral macroporous resin hemoadsorption cartridge (Jafron Biomedical), primed with heparinized saline according to the manufacturer's instructions and connected in series after the M100 hemofilter, before blood returns to the patient. Three cartridges are used consecutively, each for 6 hours (total 18 hours), starting with the first CRRT session

他の名前:
  • HA380
  • Jafron HA380 hemoperfusion cartridge

Continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (maximum 24 hours per filter), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, unfractionated heparin anticoagulation per protocol (no anticoagulation if platelet count <50 ×10⁹/L); started within 2 hours of randomization.

他の名前:
  • CRRT
  • CVVHDF
アクティブコンパレータ:CRRT Alone

Baseline CRRT (CVVHDF, Prismaflex, M100 hemofilter) without hemoadsorption. Standard septic shock care per the Surviving Sepsis Campaign 2026 guidelines.

Continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (maximum 24 hours per filter), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, unfractionated heparin anticoagulation per protocol (no anticoagulation if platelet count <50 ×10⁹/L); started within 2 hours of randomization.

他の名前:
  • CRRT
  • CVVHDF

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Arterial Blood Lactate Concentration at 24 Hours
時間枠:Baseline and 24 hours after initiation of CRRT

Arterial blood lactate (mmol/L) measured by blood gas analyzer 24 hours after initiation of CRRT, compared between groups by analysis of covariance (ANCOVA) adjusted for baseline lactate. Participants who die before 24 hours are assigned the highest lactate value observed in the study sample.

Baseline and 24 hours after initiation of CRRT

二次結果の測定

結果測定
メジャーの説明
時間枠
Vasoactive-Inotropic Score (VIS)
時間枠:Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

VIS = dopamine (µg/kg/min) + dobutamine (µg/kg/min) + 100 × epinephrine (µg/kg/min) + 100 × norepinephrine (µg/kg/min) + 10 × milrinone (µg/kg/min) + 10,000 × vasopressin (U/kg/min), according to Gaies et al. (Pediatr Crit Care Med 2010). Higher scores indicate greater vasoactive and inotropic support. Unit: points (dimensionless score).

Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
Norepinephrine Equivalent Dose (NEE)
時間枠:Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

Total vasopressor dose expressed as norepinephrine equivalents (µg/kg/min), calculated as: NEE = norepinephrine (µg/kg/min) + epinephrine (µg/kg/min) + dopamine (µg/kg/min)/100 + phenylephrine (µg/kg/min)/10 + 2.5 × vasopressin (U/min), adapted from Kotani et al. (Crit Care 2023;27:29) and restricted to the vasopressors permitted in the study protocol. Norepinephrine doses are expressed as norepinephrine base; weight-based vasopressin doses are converted to U/min using the participant's body weight. Inotropes (dobutamine, milrinone) are not included. Higher values indicate greater vasopressor requirement.

Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
Mean Arterial Pressure
時間枠:Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

Mean arterial pressure (mmHg) measured by invasive arterial monitoring.

Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
Heart Rate
時間枠:Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

Heart rate (beats per minute).

Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
Arterial Blood Lactate Concentration Over Time
時間枠:Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

Serial arterial blood lactate concentration (mmol/L) measured by blood gas analyzer at each time point. Lactate trajectories are compared between groups using a linear mixed-effects model for repeated measures adjusted for baseline lactate.

Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
Lactate Clearance
時間枠:6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

Lactate clearance (%) calculated at each time point as (baseline arterial lactate - arterial lactate at the time point) / baseline arterial lactate × 100. Positive values indicate a decrease in lactate from baseline; negative values indicate an increase.

6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
Epinephrine Dose
時間枠:Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

Epinephrine infusion dose (µg/kg/min)

Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
Number of Participants Receiving Epinephrine in the First 24 Hours
時間枠:From initiation of CRRT to 24 hours

Number of participants who receive an epinephrine infusion at any time during the first 24 hours of CRRT.

From initiation of CRRT to 24 hours
Duration of Epinephrine Infusion in the First 24 Hours
時間枠:From initiation of CRRT to 24 hours

Total duration (hours) of epinephrine infusion during the first 24 hours of CRRT.

From initiation of CRRT to 24 hours
Number of Participants With Early Shock Reversal
時間枠:6, 12, 18, 24 and 48 hours after initiation of CRRT

Early shock reversal defined as mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) together with a decrease in arterial lactate of more than 20% from baseline.

6, 12, 18, 24 and 48 hours after initiation of CRRT
Percentage Reduction in Plasma Interleukin-6 (IL-6)
時間枠:Baseline and 24 hours after initiation of CRRT

Percentage reduction in plasma IL-6 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

Baseline and 24 hours after initiation of CRRT
Percentage Reduction in Plasma Interleukin-1 Beta (IL-1β)
時間枠:Baseline and 24 hours after initiation of CRRT

Percentage reduction in plasma IL-1β concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

Baseline and 24 hours after initiation of CRRT
Percentage Reduction in Plasma Interleukin-8 (IL-8)
時間枠:Baseline and 24 hours after initiation of CRRT

Percentage reduction in plasma IL-8 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

Baseline and 24 hours after initiation of CRRT
Percentage Reduction in Plasma Interleukin-10 (IL-10)
時間枠:Baseline and 24 hours after initiation of CRRT

Percentage reduction in plasma IL-10 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

Baseline and 24 hours after initiation of CRRT
Percentage Reduction in Plasma Tumor Necrosis Factor Alpha (TNF-α)
時間枠:Baseline and 24 hours after initiation of CRRT

Percentage reduction in plasma TNF-α concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

Baseline and 24 hours after initiation of CRRT
Sequential Organ Failure Assessment (SOFA) Score
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

SOFA score (range 0-24; higher scores indicate more severe organ dysfunction), calculated by an assessor blinded to group allocation.

Baseline, day 3 and day 7 after initiation of CRRT
SOFA-2 Score
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

SOFA-2 score (range 0-24; higher scores indicate more severe organ dysfunction), calculated by an assessor blinded to group allocation.

Baseline, day 3 and day 7 after initiation of CRRT
Number of Failing Organ Systems
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Number of failing organ systems (cardiovascular, respiratory, renal, hematological, neurological, hepatic) according to Knaus criteria. Range 0-6.

Baseline, day 3 and day 7 after initiation of CRRT
Creatinine
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Blood creatinine concentration (µmol/L).

Baseline, day 3 and day 7 after initiation of CRRT
Total Bilirubin
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Blood total bilirubin concentration (µmol/L).

Baseline, day 3 and day 7 after initiation of CRRT
Platelet Count
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Platelet count (×10⁹/L).

Baseline, day 3 and day 7 after initiation of CRRT
International Normalized Ratio (INR)
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Prothrombin time expressed as INR.

Baseline, day 3 and day 7 after initiation of CRRT
C-Reactive Protein
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Blood C-reactive protein concentration (mg/L).

Baseline, day 3 and day 7 after initiation of CRRT
Procalcitonin
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Blood procalcitonin concentration (ng/mL).

Baseline, day 3 and day 7 after initiation of CRRT
Ferritin
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Blood ferritin concentration (ng/mL).

Baseline, day 3 and day 7 after initiation of CRRT
Lactate Dehydrogenase (LDH)
時間枠:Baseline, day 3 and day 7 after initiation of CRRT

Blood LDH activity (U/L).

Baseline, day 3 and day 7 after initiation of CRRT
Time to Shock Resolution
時間枠:From randomization to day 28

Time (hours) from randomization to discontinuation of the last vasopressor, with mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) maintained for at least 24 hours without vasopressors. Death before shock resolution is treated as a competing event.

From randomization to day 28
Number of Participants With Shock Resolution
時間枠:From randomization to day 28

Shock resolution defined as complete discontinuation of vasopressors with mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) maintained for at least 24 hours without reintroduction.

From randomization to day 28
Number of Participants With Recurrent Shock
時間枠:From randomization to day 28

Recurrent shock defined as reintroduction of vasopressors after shock resolution.

From randomization to day 28
Vasopressor-Free Days
時間枠:From randomization to day 28

Number of days alive and free of vasopressors within 28 days after randomization; participants who die before day 28 are assigned 0 days.

From randomization to day 28
Ventilator-Free Days
時間枠:From randomization to day 28

Number of days alive and free of invasive mechanical ventilation within 28 days after randomization; participants who die before day 28 are assigned 0 days.

From randomization to day 28
Renal Replacement Therapy-Free Days
時間枠:From randomization to day 28

Number of days alive and free of any renal replacement therapy within 28 days after randomization; participants who die before day 28 are assigned 0 days.

From randomization to day 28
ICU-Free Days
時間枠:From randomization to day 28

Number of days alive and out of the ICU within 28 days after randomization; participants who die before day 28 are assigned 0 days.

From randomization to day 28
Number of Participants Dependent on Renal Replacement Therapy
時間枠:Day 7 and day 28 after randomization

Dialysis dependence defined as still requiring any form of renal replacement therapy on the day of assessment.

Day 7 and day 28 after randomization
Duration of Invasive Mechanical Ventilation
時間枠:From randomization to ICU discharge, assessed up to 28 days

Number of days on invasive mechanical ventilation.

From randomization to ICU discharge, assessed up to 28 days
Duration of CRRT
時間枠:From initiation of CRRT to ICU discharge, assessed up to 28 days

Number of days on continuous renal replacement therapy.

From initiation of CRRT to ICU discharge, assessed up to 28 days
Number of M100 Hemofilters Used
時間枠:From initiation of CRRT to ICU discharge, assessed up to 28 days

Total number of M100 hemofilters used during the ICU stay.

From initiation of CRRT to ICU discharge, assessed up to 28 days
Lifespan of the First M100 Hemofilter
時間枠:From initiation of CRRT to 24 hours

Time (hours) from start of the first M100 hemofilter to its replacement (maximum 24 hours per protocol).

From initiation of CRRT to 24 hours
ICU Length of Stay
時間枠:From ICU admission to ICU discharge, assessed up to 28 days

Number of days from ICU admission to ICU discharge.

From ICU admission to ICU discharge, assessed up to 28 days
Hospital Length of Stay
時間枠:From hospital admission to hospital discharge, assessed up to 28 days

Number of days from hospital admission to hospital discharge.

From hospital admission to hospital discharge, assessed up to 28 days
ICU Mortality
時間枠:From randomization to ICU discharge, assessed up to 28 days

Number of participants who die from any cause during the ICU stay.

From randomization to ICU discharge, assessed up to 28 days
In-Hospital Mortality
時間枠:From randomization to hospital discharge, assessed up to 28 days

Number of participants who die from any cause during the hospital stay. Participants discharged in critical condition at the family's request are followed up by telephone.

From randomization to hospital discharge, assessed up to 28 days
7-Day All-Cause Mortality
時間枠:From randomization to day 7

Number of participants who die from any cause within 7 days after randomization.

From randomization to day 7
28-Day All-Cause Mortality
時間枠:From randomization to day 28

Number of participants who die from any cause within 28 days after randomization.

From randomization to day 28
Number of Participants With Hypotension at CRRT Initiation or HA380 Cartridge Change
時間枠:Within 30 minutes after CRRT initiation and after cartridge changes at 6, 12 and 18 hours

Hypotension defined as a decrease in mean arterial pressure (invasive monitoring) of more than 20% from the pre-connection value, or to <65 mmHg (<60 mmHg in patients aged ≥65 years), requiring an increase in vasopressor dose, within 30 minutes after connection of the CRRT circuit or after each HA380 cartridge change.

Within 30 minutes after CRRT initiation and after cartridge changes at 6, 12 and 18 hours
Number of Participants With Bleeding Events
時間枠:From initiation of CRRT to day 7

Treatment-emergent bleeding (catheter site, upper gastrointestinal or intracranial), identified by daily clinical monitoring and confirmed by investigations when clinically indicated, graded by CTCAE version 6.0.

From initiation of CRRT to day 7
Number of Participants With Thrombocytopenia
時間枠:From initiation of CRRT to day 7

Treatment-emergent thrombocytopenia defined as a platelet count decrease of ≥50% from baseline, severity graded by CTCAE version 6.0 according to the lowest platelet count. Platelet counts are obtained at baseline, day 3 and day 7, and whenever clinically indicated.

From initiation of CRRT to day 7
Number of Participants With Hemolysis
時間枠:From initiation of CRRT to day 7

Hemolysis defined as a hemoglobin decrease of ≥20 g/L with laboratory evidence of hemolysis (elevated LDH, decreased haptoglobin, and/or schistocytes on peripheral smear), graded by CTCAE version 6.0. Assessed by laboratory tests at baseline, day 3 and day 7, and whenever hemolysis is clinically suspected.

From initiation of CRRT to day 7
Number of Participants With Electrolyte Disturbances
時間枠:From initiation of CRRT until end of CRRT or day 7, whichever comes first

Treatment-emergent electrolyte disturbance defined as potassium <3.0 mmol/L, phosphate <0.6 mmol/L, ionized calcium <0.9 mmol/L or magnesium <0.5 mmol/L, graded by CTCAE version 6.0.

From initiation of CRRT until end of CRRT or day 7, whichever comes first
Number of Participants With Hypothermia
時間枠:From initiation of CRRT until end of CRRT or day 7, whichever comes first

Core temperature <35°C during CRRT, based on hourly core temperature monitoring (lowest value recorded every 6 hours in the first 24 hours, then daily), graded by CTCAE version 6.0.

From initiation of CRRT until end of CRRT or day 7, whichever comes first
Number of Participants With Anaphylaxis
時間枠:From initiation of CRRT to 72 hours

Anaphylaxis according to the Vietnamese Ministry of Health diagnostic criteria, graded by CTCAE version 6.0.

From initiation of CRRT to 72 hours
Number of Participants With Catheter Occlusion
時間枠:From initiation of CRRT to day 14

Dialysis catheter occlusion by clot requiring interruption of CRRT and catheter replacement.

From initiation of CRRT to day 14
Number of Participants With Catheter-Site Infection
時間枠:From initiation of CRRT to day 14

Swelling, erythema, discharge or pus within 2 cm of the dialysis catheter insertion site, graded by CTCAE version 6.0.

From initiation of CRRT to day 14
Number of Participants With Catheter-Related Venous Thrombosis
時間枠:From initiation of CRRT to day 14

Venous thrombosis related to the dialysis catheter, confirmed by ultrasound, graded by CTCAE version 6.0.

From initiation of CRRT to day 14
Number of Participants With Extracorporeal Circuit Incidents
時間枠:From initiation of CRRT until end of CRRT or 72 hours, whichever comes first

Number of participants with at least one device deficiency (ISO 14155:2026): hemofilter membrane rupture (blood leak alarm with pink/red effluent); M100 hemofilter clotting requiring unplanned circuit change (TMP >300 mmHg or unresolved clotting alarm, visible clot, or blood pump stopped by clot); early HA380 clotting requiring removal before 6 hours; or unplanned technical stoppage of the blood pump for ≥15 minutes. Each stoppage is attributed to one primary cause. The number of events per participant is also reported.

From initiation of CRRT until end of CRRT or 72 hours, whichever comes first

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Bui Viet Hoan, MD、The 108 Military Central Hospital
  • スタディチェア:Pham Dang Hai, MD, PhD、The 108 Military Central Hospital
  • スタディチェア:Le Xuan Duong, MD, PhD、The 108 Military Central Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年10月1日

研究の完了 (推定)

2028年11月1日

試験登録日

最初に提出

2026年11月14日

QC基準を満たした最初の提出物

2026年11月14日

最初の投稿 (実際)

2026年11月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月14日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 7197/GCN-BV

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be made publicly available because consent for public data sharing was not obtained in this single-center study. Aggregate results will be published in peer-reviewed journals and reported on ClinicalTrials.gov.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。